| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Victor Sapena, Massimo Iavarone, Loreto Boix, Floriana Facchetti, Maria Guarino, Marco Sanduzzi Zamparelli, Alessandro Granito, Esther Samper, Mario Scartozzi, Josep Corominas, Giorgia Marisi, Alba Diaz, Andrea Casadei-Gardini, Laura Gramantieri, Pietro Lampertico, Filomena Morisco, Ferran Torres, Jordi Bruix and Maria Reig |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Maria Reig, PhD, Chief Physician, Research Scientist, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Universidad de Barcelona, CIBEREHD, Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Universidad de Barcelona, CIBEREHD, Barcelona, Spain. Hospital Clínic, C/ Villarroel, 170, Escala 11, 4a planta, 08036 Barcelona. Spain. Tel.: +34 932279803, fax: +34 32275792. mreig1@clinic.cat., Barcelona 08036, Spain. mreig1@clinic.cat |
| Key Words |
HCC; Early DAE; Single-nucleotide polymorphisms; AGT1 (rs699); AGT2 (rs4762), Tyrosine kinase inhibitors |
| Core Tip |
Dermatologic adverse events (DAEs) are associated with a better outcome in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent received. Our study shows that DAE development in these patients can be explained by individual genetic variants in the AGT2 gene. AGT2 (rs4762) AA genotype was associated with DAE risk in the Northern Italy cohort and was externally validated in a cohort combining the BCLC1, BCLC2 and Naples cohorts. Therefore, DAE development in HCC patients receiving TKIs can be explained by the AGT2 (rs4762) gene variant. If validated in other anti-oncogenic treatments, it might be considered a good prognosis marker. |
| Publish Date |
2022-07-27 13:17 |
| Citation |
Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, Granito A, Samper E, Scartozzi M, Corominas J, Marisi G, Diaz A, Casadei-Gardini A, Gramantieri L, Lampertico P, Morisco F, Torres F, Bruix J, Reig M. Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib. World J Hepatol 2022;14(7): 1438-1458 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i7/1438.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i7.1438 |
